Parexel posts huge bookings & begins another hiring spree 02-May-2012 By Nick Taylor Gross bookings at Parexel topped $1bn in the third quarter but the need to accelerate hiring again led to a cut to earnings guidance.
PPD accepts $3.9bn offer PPD accepts $3.9bn offer 04-Oct-2011 By Nick Taylor PPD has agreed to be acquired by two private equity firms for $3.9bn (€3.0bn) in cash.
CROs' complex demands are changing the tissue supply biz, says industry expert 27-Sep-2011 By Natalie Morrison The human tissue supply industry is under pressure from CROs demanding more complex samples, according to equity analyst Vadim Alexandre.
CEO hire signals private equity unlikely to buy PPD; analyst CEO hire signals private equity unlikely to buy PPD; analyst 20-Sep-2011 By Nick Taylor PPD has named a new CEO and is now unlikely to be taken over by private equity because the deal environment has worsened, an equity analyst said.
Strategic deals, biotech return to boost CROs’ biz in ‘12 Strategic deals, biotech return to boost CROs’ biz in ‘12 13-Sep-2011 By Nick Taylor CRO performance across late stage, Phase I and central laboratories should improve in 2012 as strategic deals develop and smaller clients return, an analyst said.
INC Research to buy Kendle & aim at top 5 clinical CROs INC Research to buy Kendle & aim at top 5 clinical CROs 05-May-2011 By Nick Taylor INC Research is to acquire Kendle in a deal that would give it Phase II to IV clinical assets comparable to those at Covance.